PBAC's latest decision on Dapagliflozin with metformin: Deferred (2017). Considered for Type 2 diabetes mellitus as triple oral therapy in combination with a dipeptidyl peptidase 4 (DPP4) inhibitor in patients uncontrolled on dual oral therapy.
PBAC outcome
Deferred
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2017
Submissions
1
2017 → 2017
Eligible population
Adults with type 2 diabetes mellitus uncontrolled on dual oral therapy (metformin and a DPP4 inhibitor) requiring triple oral therapy.
Therapy area
Endocrinology
Line of therapy
Later-line
Evidence base
RCT
Primary endpoint
Other
Key trials
Study 129, Study 10
Comparator
co-administered individual components (dapagliflozin and metformin taken separately)
Economic model
Cost-minimisation
ICER note
No economic comparison provided; minor submission submitted on cost-minimisation basis to component parts.